---
document_datetime: 2023-09-21 18:28:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/nulojix-epar-all-authorised-presentations_en.pdf
document_name: nulojix-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7550118
conversion_datetime: 2025-12-18 23:05:52.170906
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical Form                              | Route of administration   | Packaging                       | Content (concentration)   | Package size         |
|-----------------|-----------------|------------|--------------------------------------------------|---------------------------|---------------------------------|---------------------------|----------------------|
| EU/1/11/694/001 | Nulojix         | 250 mg     | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass); syringe (plastic) | 25 mg/ml                  | 1 vial + 1 syringe   |
| EU/1/11/694/002 | Nulojix         | 250 mg     | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass); syringe (plastic) | 25 mg/ml                  | 2 vials + 2 syringes |